The U.S. Food and Drug Administration approved 46 new therapies in 2017, up from only 22 the year before. The following is a list of the new medications for neurology and psychiatry. Read More
Neurology
Long-term efficacy, safety of DMTs in MS
December 20, 2017SPECIAL REPORT
7TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017
Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab Read More
Cladribine tablets (Mavenclad) approved in Canada for RRMS
December 4, 2017Health Canada has approved cladribine tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS), to reduce the frequency of clinical exacerbations and delay the progression of disability. The drug, marketed as Mavenclad, may be used for newly-diagnosed patients, but is generally recommended in MS patients with an inadequate response or poor tolerability to a prior MS therapy. Read More
Cladribine tablets – Updated efficacy and safety results
November 28, 2017Cladribine tablets, a novel intermittent immunosuppressant expected soon in North America, has been shown to be highly efficacious in reducing annualized relapse rates (ARR) and disability progression over a sustained period, according to the most recent data. Read More
ECTRIMS 2017 SLIDE DECK
November 9, 2017Selected highlights of ECTRIMS – ACTRIMS 2017
Paris, France – 25-28 October 2017
34 slides
Click here to download the ECTRIMS 2017 Slide Deck
Scientific review:
Dr. Daniel Selchen, Chief of Neurology, St. Michael’s Hospital, Toronto, Canada